Search research articles
Contact Us
Filters
Showing results (441-450 of 487) with videos related to
Page
of 49
Sort By:
Cancer Medicine
|
February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma
Omar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
NPJ Precision Oncology
|
October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
Henry Hiep Vo, Siqing Fu, David S Hong, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
David R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Journal of the Advanced Practitioner in Oncology
|
October 6, 2022
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience
Fedricker D Barber, Erick Campbell, Yuko Yamamura, et al.
ESMO Open
|
October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
Aparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
Thyroid : Official Journal of the American Thyroid Association
|
February 10, 2023
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF<sup>V600E</sup> Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study
Xiao Zhao, Jennifer Rui Wang, Ramona Dadu, et al.
The New England Journal of Medicine
|
August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M Hyman, Igor Puzanov, Vivek Subbiah, et al.
Molecular Cancer Research : MCR
|
December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
Tito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Scientific Reports
|
August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
Tito R Mendoza, David S Hong, Christine B Peterson, et al.
Page
of 49
Search research articles
Search
Showing results (441-450 of 487) with videos related to
Sort By:
Page
of 49
Cancer Medicine
|
February 13, 2025
A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma
Omar Alhalabi, Mohamed A Gouda, Denái R Milton, et al.
NPJ Precision Oncology
|
October 27, 2022
Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology
Henry Hiep Vo, Siqing Fu, David S Hong, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
David R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Journal of the Advanced Practitioner in Oncology
|
October 6, 2022
Management of Adverse Events in Early Clinical Trials by Advanced Practice Providers in the Outpatient Setting: The University of Texas MD Anderson Cancer Center Experience
Fedricker D Barber, Erick Campbell, Yuko Yamamura, et al.
ESMO Open
|
October 24, 2020
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
Aparna Hegde, Alexander Y Andreev-Drakhlin, Jason Roszik, et al.
Thyroid : Official Journal of the American Thyroid Association
|
February 10, 2023
Surgery After BRAF-Directed Therapy Is Associated with Improved Survival in BRAF<sup>V600E</sup> Mutant Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Study
Xiao Zhao, Jennifer Rui Wang, Ramona Dadu, et al.
The New England Journal of Medicine
|
August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M Hyman, Igor Puzanov, Vivek Subbiah, et al.
Molecular Cancer Research : MCR
|
December 16, 2020
Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes
Omar Alhalabi, Andrew W Hahn, Pavlos Msaouel, et al.
Journal for Immunotherapy of Cancer
|
October 24, 2020
Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory
Tito Mendoza, Ajay Sheshadri, Mehmet Altan, et al.
Scientific Reports
|
August 23, 2022
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
Tito R Mendoza, David S Hong, Christine B Peterson, et al.
Page
of 49